Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine

Open Access 08-05-2024 | Meningioma | Original Article

11C-Methionine uptake in meningiomas after stereotactic radiotherapy

Authors: Hanne-Rinck Jeltema, Bart R. J. van Dijken, Katalin Tamási, Gea Drost, Mart A. A. M. Heesters, Anouk van der Hoorn, Andor W. J. M. Glaudemans, J. Marc C. van Dijk

Published in: Annals of Nuclear Medicine

Login to get access

Abstract

Objective

11C-Methionine positron emission tomography (MET-PET) is used for stereotactic radiotherapy planning in meningioma patients. The role of MET-PET during subsequent follow-up (FU) is unclear. We analyzed the uptake of 11C-Methionine before and after stereotactic radiotherapy (SRT) in patients with a complex meningioma and investigated if there was a difference between patients with progressive disease (PD) and stable disease (SD) during FU.

Methods

This retrospective study investigates 62 MET-PETs in 29 complex meningioma patients. Standardized uptake value (SUV)max and SUVpeak tumor-to-normal ratios (T/N-ratios) were calculated, comparing the tumor region with both the mirroring intracranial area and the right frontal gray matter. The difference in 11C-Methionine uptake pre- and post-SRT was analyzed, as well as the change in uptake between PD or SD.

Results

Median (IQR) FU duration was 67 months (50.5–91.0). The uptake of 11C-Methionine in meningiomas remained increased after SRT. Neither a statistically significant difference between MET-PETs before and after SRT was encountered, nor a significant difference in one of the four T/N-ratios between patients with SD versus PD with median (IQR) SUVmax T/NR front 2.65 (2.13–3.68) vs 2.97 (1.55–3.54) [p = 0.66]; SUVmax T/Nmirror 2.92 (2.19–3.71) vs 2.95 (1.74–3.60) [p = 0.61]; SUVpeak T/NR front 2.35 (1.64–3.40) vs 2.25 (1.44–3.74) [p = 0.80]; SUVpeak T/Nmirror 2.38 (1.91–3.36) vs 2.35 (1.56–3.72) [p = 0.95].

Conclusions

Our data do not support use of MET-PET during FU of complex intracranial meningiomas after SRT. MET-PET could not differentiate between progressive or stable disease.
Appendix
Available only for authorised users
Literature
1.
Alexiou GA, Gogou P, Markoula S, Kyritsis AP. Management of meningiomas. Clin Neurol Neurosurg. 2010;112:177–82.PubMedCrossRef
2.
3.
Glaudemans AWJM, Enting RH, Heesters MAAM, Dierckx RAJO, Van Rheenen RWJ, Walenkamp AME, et al. Value of 11C-Methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging. 2013;40:615–35.PubMedCrossRef
4.
Tripathi M, Sharma R, Varshney R, Jaimini A, Jain J, Souza MMD, et al. Comparison of F-18 FDG and C-11 Methionine PET/CT for the evaluation of recurrent primary brain tumors. Clin Nucl Med. 2012;37(2):158–63.PubMedCrossRef
5.
Ceccon G, Lohmann P, Werner JM, Tscherpel C, Dunkl V, Stoffels G, et al. Early treatment response assessment using 18F-FET PET compared with contrast-enhanced MRI in glioma patients after adjuvant temozolomide chemotherapy. J Nucl Med. 2021;62(7):918–25.PubMedCrossRef
6.
Langen KJ, Stoffels G, Filss C, Heinzel A, Stegmayr C, Lohmann P, et al. Imaging of amino acid transport in brain tumours: positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine (FET). Methods. 2017;130:124–34.PubMedCrossRef
7.
Laukamp KR, Lindemann F, Weckesser M, Hesselmann V, Ligges S, Wölfer J, et al. Multimodal imaging of patients with gliomas confirms 11C-MET PET as a complementary marker to MRI for noninvasive tumor grading and intraindividual follow-up after therapy. Mol Imaging. 2017;16:1–12.CrossRef
8.
Rapp M, Heinzel A, Galldiks N, Stoffels G, Felsberg J, Ewelt C, et al. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med. 2013;54(2):229–35.PubMedCrossRef
9.
Cornelius JF, Stoffels G, Filß C, Galldiks N, Slotty P, Kamp M, et al. Uptake and tracer kinetics of O-(2–18F-fluoroethyl)-l-tyrosine in meningiomas: preliminary results. Eur J Nucl Med Mol Imaging. 2015;42(3):459–67.PubMedCrossRef
10.
Basse V, Dissaux G, Seizeur R, Bourhis D, Querellou S. Uptake and tracer kinetic of O-(2-(18)F-fluoroethyl)-l-tyrosine in meningioma. Clin Nucl Med. 2019;44(1):e22–3.PubMedCrossRef
11.
Yomo S, Oguchi K. Prospective study of 11C-Methionine PET for distinguishing between recurrent brain metastases and radiation necrosis: limitations of diagnostic accuracy and long-term results of salvage treatment. BMC Cancer. 2017;17(1):1.CrossRef
12.
Tomura N, Kokubun M, Saginoya T, Mizuno Y, Kikuchi Y. Differentiation between treatment-induced necrosis and recurrent tumors in patients with metastatic brain tumors: comparison among 11C-Methionine-PET, FDG-PET, MR permeability imaging, and MRI-ADC-preliminary results. Am J Neuroradiol. 2017;38(8):1520–7.PubMedPubMedCentralCrossRef
13.
Ceccon G, Lohmann P, Stoffels G, Judov N, Filss CP, Rapp M, et al. Dynamic O-(2–18F-fluoroethyl)-l-tyrosine positron emission tomography differentiates brain metastasis recurrence from radiation injury after radiotherapy. Neuro Oncol. 2017;19(2):281–8.PubMed
14.
Nuutinen J, Sonninen P, Lehikoinen P, Sutinen E, Valavaara R, Eronen E, et al. Radiotherapy treatment planning and long-term follow-up with [11 C]Methionine PET in patients with low-grade astrocytoma. Int J Radiot Oncol Biol Phys. 2000;48(1):43–52.CrossRef
15.
Mattoli MV, Trevisi G, Scolozzi V, Capotosti A, Cocciolillo F, Marini I, et al. Dynamic 11C-Methionine PET-CT: prognostic factors for disease progression and survival in patients with suspected glioma recurrence. Cancers. 2021;13(19):47777.CrossRef
16.
Astner ST, Dobrei-Ciuchendea M, Essler M, Bundschuh RA, Sai H, Schwaiger M, et al. Effect of 11C-Methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas. Int J Radiat Oncol Biol Phys. 2008;72(4):1161–7.PubMedCrossRef
17.
Kessel KA, Weber W, Yakushev I, Fischer H, Voglhuber T, Diehl C, et al. Integration of PET-imaging into radiotherapy treatment planning for low-grade meningiomas improves outcome. Eur J Nucl Med Mol Imaging. 2020;47(6):1391–9.PubMedCrossRef
18.
Grosu AL, Weber WA, Astner ST, Adam M, Krause BJ, Schwaiger M, et al. 11C-Methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66(2):339–44.PubMedCrossRef
19.
Kits A, Martin H, Sanchez-Crespo A, Delgado AF. Diagnostic accuracy of 11C-Methionine PET in detecting neuropathologically confirmed recurrent brain tumor after radiation therapy. Ann Nucl Med. 2018;32(2):132–41.PubMedCrossRef
20.
Pyka T, Hiob D, Preibisch C, Gempt J, Wiestler B, Schlegel J, et al. Diagnosis of glioma recurrence using multiparametric dynamic 18F-fluoroethyl-tyrosine PET-MRI. Eur J Radiol. 2018;103:32–7.PubMedCrossRef
21.
Xu W, Gao L, Shao A, Zheng J, Zhang J. The performance of 11C-Methionine PET in the differential diagnosis of glioma recurrence. Oncotarget. 2017;8(53):91030–9.PubMedPubMedCentralCrossRef
22.
23.
24.
Galldiks N, Albert NL, Sommerauer M, Grosu AL, Ganswindt U, Law I, et al. PET imaging in patients with meningioma—report of the RANO/PET group. Neuro Oncol. 2017;19(12):1576–87.PubMedPubMedCentralCrossRef
25.
Galldiks N, Albert NL, Wollring M, Werner JM, Lohmann P, Villanueva-Meyer JE, et al. Advances in PET imaging for meningioma patients. Neurooncol Adv. 2023;5:I84-93.PubMedPubMedCentral
26.
Galldiks N, Langen KJ. Amino acid PET—an imaging option to identify treatment response, posttherapeutic effects, and tumor recurrence? Front Neurol. 2016;7:120.PubMedPubMedCentralCrossRef
27.
Pekošak A, Filp U, Poot AJ, Windhorst AD. From carbon-11-labeled amino acids to peptides in positron emission tomography: the synthesis and clinical application. Mol Imaging Biol. 2018;20(4):510–32.PubMedCrossRef
28.
Ryttlefors M, Danfors T, Latini F, Montelius A, Blomquist E, Gudjonsson O. Long-term evaluation of the effect of hypofractionated high-energy proton treatment of benign meningiomas by means of 11C-l-Methionine positron emission tomography. Eur J Nucl Med Mol Imaging. 2016;43(8):1432–43.PubMedCrossRef
29.
Ikeda H, Tsuyuguchi N, Kunihiro N, Ishibashi K, Goto T, Ohata K. Analysis of progression and recurrence of meningioma using 11C-Methionine PET. Ann Nucl Med. 2013;27(8):772–80.PubMedCrossRef
30.
Gudjonsson O, Blomquist E, Lilja A, Ericson H, Bergström M, Nyberg G. Evaluation of the effect of high-energy proton irradiation treatment on meningiomas by means of 11C-l-Methionine PET. Eur J Nucl Med. 2000;27(12):1793–9.PubMedCrossRef
31.
Jeltema H-R, Jansen MR, Potgieser ARE, van Asselt ADI, Heesters MAAM, van de Hoorn A, et al. Study on intracranial meningioma using PET ligand investigation during follow-up over years (SIMPLIFY). Neuroradiology. 2021;63(11):1792–9.CrossRef
32.
Vander Borght T, Asenbaum S, Bartenstein P, Halldin C, Kapucu Ö, Van Laere K, et al. EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging. 2006;33(11):1374–80.PubMedCrossRef
33.
Korimerla N, Wahl DR. Interactions between radiation and one-carbon metabolism. Int J Mol Sci. 2022;23(3):1–14.CrossRef
34.
Cuccurullo V, Di Stasio GD, Cascini GL, Gatta G, Bianco C. The molecular effects of ionizing radiations on brain cells: radiation necrosis vs. tumor recurrence. Diagnostics. 2019;9(4):127.PubMedPubMedCentralCrossRef
35.
Suchorska B, Unterrainer M, Biczok A, Sosnova M, Forbrig R, Bartenstein P, et al. 18F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy. J Neurooncol. 2018;139(3):721–30.PubMedCrossRef
36.
Heinzel A, Dedic D, Galldiks N, Lohmann P, Stoffels G, Filss CP, et al. Two decades of brain tumour imaging with O-(2-[18F]fluoroethyl)-l-tyrosine PET: the Forschungszentrum Jülich experience. Cancers. 2022;14(14):3336.PubMedPubMedCentralCrossRef
37.
Afshar-Oromieh A, Wolf MB, Kratochwil C, Giesel FL, Combs SE, Dimitrakopoulou-Strauss A, et al. Comparison of 68 Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: Initial results. Neuro Oncol. 2015;17(2):312–9.PubMedCrossRef
38.
Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L, Pöschl J, et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. J Nucl Med. 2015;56(3):347–53.PubMedCrossRef
39.
Kowalski ES, Khairnar R, Gryaznov AA, Kesari V, Koroulakis A, Raghavan P, et al. 68Ga-DOTATATE PET-CT as a tool for radiation planning and evaluating treatment responses in the clinical management of meningiomas. Radiat Oncol. 2021;16(1):151.PubMedPubMedCentralCrossRef
40.
Ivanidze J, Roytman M, Lin E, Magge RS, Pisapia DJ, Liechty B, et al. Gallium-68 DOTATATE PET in the evaluation of intracranial meningiomas. J Neuroimaging. 2019;29(5):650–6.PubMedCrossRef
41.
Afshar-Oromieh A, Giesel FL, Linhart HG, Haberkorn U, Haufe S, Combs SE, et al. Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging. 2012;39(9):1409–15.PubMedCrossRef
42.
Pelak M, D’Amico A. The Prognostic value of pretreatment gallium-68 DOTATATE positron emission tomography/computed tomography in irradiated non-benign meningioma. Indian J Nucl Med. 2019;34(4):278–83.PubMedPubMedCentralCrossRef
43.
Stade F, Dittmar JO, Jäkel O, Kratochwil C, Haberkorn U, Debus J, et al. Influence of 68Ga-DOTATOC on sparing of normal tissue for radiation therapy of skull base meningioma: differential impact of photon and proton radiotherapy. Radiat Oncol. 2018;13(1):58.PubMedPubMedCentralCrossRef
44.
Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A, et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006;65(1):222–7.PubMedCrossRef
45.
Mahase SS, Roth O’Brien DA, No D, Roytman M, Skafida ME, Lin E, et al. [68Ga]-DOTATATE PET/MRI as an adjunct imaging modality for radiation treatment planning of meningiomas. Neurooncol Adv. 2021;3(1):vdab012.PubMedPubMedCentral
46.
Dittmar JO, Kratochwil C, Dittmar A, Welzel T, Habermehl D, Rieken S, et al. First intraindividual comparison of contrast-enhanced MRI, FET- and DOTATOC- PET in patients with intracranial meningiomas. Radiat Oncol. 2017;12(1):169.PubMedPubMedCentralCrossRef
47.
Sommerauer M, Burkhardt JK, Frontzek K, Rushing E, Buck A, Krayenbuehl N, et al. 68Gallium-DOTATATE PET in meningioma: a reliable predictor of tumor growth rate? Neuro Oncol. 2016;18(7):1021–7.PubMedPubMedCentralCrossRef
48.
Barone F, Inserra F, Scalia G, Ippolito M, Cosentino S, Crea A, et al. 68Gga-dotatoc pet/ct follow up after single or hypofractionated gamma knife icon radiosurgery for meningioma patients. Brain Sci. 2021;11(3):375.PubMedPubMedCentralCrossRef
49.
Lütgendorf-Caucig C, Pelak M, Flechl B, Georg P, Fossati P, Stock M, et al. The trends and significance of SSTR PET/CT added to MRI in follow-up imaging of low-grade meningioma treated with fractionated proton therapy. Strahlenther Onkol. 2022;199(4):396–403.PubMedCrossRef
Metadata
Title
11C-Methionine uptake in meningiomas after stereotactic radiotherapy
Authors
Hanne-Rinck Jeltema
Bart R. J. van Dijken
Katalin Tamási
Gea Drost
Mart A. A. M. Heesters
Anouk van der Hoorn
Andor W. J. M. Glaudemans
J. Marc C. van Dijk
Publication date
08-05-2024
Publisher
Springer Nature Singapore
Published in
Annals of Nuclear Medicine
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-024-01932-6